Field performance of a thin-layer chromatography assay for detection of nevirapine in umbilical cord blood

被引:12
作者
Chi, Benjamin H.
Lee, Alison
Acosta, Edward P.
Westerman, Larry E.
Sinkala, Moses
Stringer, Jeffrey S. A.
机构
[1] Ctr Infect Dis Res Zambia, Lusaka, Zambia
[2] Univ Alabama, Sch Med, Birmingham, AL 35294 USA
[3] Univ Alabama, Sch Publ Hlth, Birmingham, AL 35294 USA
[4] Lusaka Urban Dist Hlth Management Board, Lusaka, Zambia
来源
HIV CLINICAL TRIALS | 2006年 / 7卷 / 05期
关键词
HIV; nevirapine; prevention of mother-to-child transmission of HIV; PMTCT; surveillance; thin-layer chromatography;
D O I
10.1310/hct0705-263
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Purpose: Although cord blood surveillance can measure the effectiveness of nevirapine (NVP)-based programs for the prevention of mother-to-child HIV transmission (PMTCT), it requires the ability to detect nevirapine in plasma. At present, the only validated method is high-performance liquid chromatography (HPLC), a technique poorly suited for most resource-constrained settings. Method: We evaluated the field performance for a simple and inexpensive thin-layer chromatography (TLC) assay for NVP detection. We developed a conditional probability model to compare 2 testing algorithms: HPLC alone, and TLC screening followed by HPLC confirmation of negative results. Results: When compared to HPLC, sensitivity of TLC was 0.67 (95% confidence interval [CI] 0.49-0.84) and specificity was 0.84 (95% CI 0.69-0.95). In this sample-where overall NVP coverage was 49%-positive predictive value was 0.80 and negative predictive value was 0.72. At baseline with population NVP coverage of 33%, cost per specimen was lower in the TLC-HPLC testing algorithm ($40 vs. $50), and the proportion of false results was acceptable (11%). As population NVP coverage increased, cost-efficiency improved and error rate dropped substantially. Conclusion: TLC is reasonably sensitive and specific for NVP detection. A 2-step testing algorithm incorporating TLC and HPLC provides cost-efficiency at little expense to test performance.
引用
收藏
页码:263 / 269
页数:7
相关论文
共 18 条
[1]   Predictors of nonadherence to single-dose nevirapine therapy for the prevention of mother-to-child HIV transmission [J].
Albrecht, S ;
Semrau, K ;
Kasonde, P ;
Sinkala, M ;
Kankasa, C ;
Vwalika, C ;
Aldrovandi, GM ;
Thea, DM ;
Kuhn, L .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2006, 41 (01) :114-118
[2]   Timing of maternal and neonatal dosing of nevirapine and the risk of mother-to-child transmission of HIV-1: HIVNET 024 [J].
Chi, BH ;
Wang, L ;
Read, JS ;
Sheriff, M ;
Fiscus, S ;
Brown, ER ;
Taha, TE ;
Valentine, M ;
Goldenberg, R .
AIDS, 2005, 19 (16) :1857-1864
[3]   High-performance liquid chromatographic assay to determine the plasma levels of HIV-protease inhibitors (amprenavir, indinavir, nelfinavir, ritonavir and saquinavir) and the non-nucleoside reverse transcriptase inhibitor (nevirapine) after liquid-liquid extraction [J].
Dailly, E ;
Thomas, L ;
Kergueris, MF ;
Jolliet, P ;
Bourin, M .
JOURNAL OF CHROMATOGRAPHY B, 2001, 758 (02) :129-135
[4]   Detection of nevirapine in plasma using thin-layer chromatography [J].
Dubuisson, JG ;
King, JR ;
Stringer, JSA ;
Turner, ML ;
Bennetto, C ;
Acosta, EP .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2004, 35 (02) :155-157
[5]   Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVMET 012 randomised trial [J].
Guay, LA ;
Musoke, P ;
Fleming, T ;
Bagenda, D ;
Allen, M ;
Nakabiito, C ;
Sherman, J ;
Bakaki, P ;
Ducar, C ;
Deseyve, M ;
Emel, L ;
Mirochnick, M ;
Fowler, MG ;
Mofenson, L ;
Miotti, P ;
Dransfield, K ;
Bray, D ;
Mmiro, F ;
Jackson, JB .
LANCET, 1999, 354 (9181) :795-802
[6]   Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial [J].
Jackson, JB ;
Musoke, P ;
Fleming, T ;
Guay, LA ;
Bagenda, D ;
Allen, M ;
Nakabiito, C ;
Sherman, J ;
Bakaki, P ;
Owor, M ;
Ducar, C ;
Deseyve, M ;
Mwatha, A ;
Emel, L ;
Duefield, C ;
Mirochnick, M ;
Fowler, MG ;
Mofenson, L ;
Miotti, P ;
Gigliotti, M ;
Bray, D ;
Mmiro, F .
LANCET, 2003, 362 (9387) :859-868
[7]   Field acceptability and effectiveness of the routine utilization of zidovudine to reduce mother-to-child transmission of HIV-1 in West Africa [J].
Meda, N ;
Leroy, V ;
Viho, I ;
Msellati, P ;
Yaro, S ;
Mandelbrot, L ;
Montcho, C ;
Manigart, O ;
Dabis, F .
AIDS, 2002, 16 (17) :2323-2328
[8]   A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1 [J].
Moodley, D ;
Moodley, J ;
Coovadia, H ;
Gray, G ;
McIntyre, J ;
Hofmyer, J ;
Nikodem, C ;
Hall, D ;
Gigliotti, M ;
Robinson, P ;
Boshoff, L ;
Sullivan, JL .
JOURNAL OF INFECTIOUS DISEASES, 2003, 187 (05) :725-735
[9]   Women's reasons for not participating in follow up visits before starting short course antiretroviral prophylaxis for prevention of mother to child transmission of HIV: qualitative interview study [J].
Painter, TM ;
Diaby, KL ;
Matia, DM ;
Lin, LS ;
Sibailly, TS ;
Kouassi, MK ;
Ekpini, ER ;
Roels, TH ;
Wiktor, SZ .
BMJ-BRITISH MEDICAL JOURNAL, 2004, 329 (7465) :543-546
[10]  
STRINGER EM, 2004, 15 INT AIDS C BANGK